{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:01:17Z","timestamp":1793721677817,"version":"4.6.1"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:p>Dry eye disease (DED) is a common chronic ocular surface disorder that significantly impacts quality of life. Its pathogenesis involves disruption of immune regulatory mechanisms and ocular surface inflammation, which mutually reinforce each other in a vicious cycle. Conventional treatments, such as artificial tears and meibomian gland care, alleviate symptoms but often fail to control underlying inflammation. Anti-inflammatory therapy is therefore crucial. Traditional agents like corticosteroids provide rapid relief but carry risks with long-term use. Cyclosporine A, an immunosuppressant, offers unique advantages by inhibiting T-cell activation, reducing pro-inflammatory cytokines, enhancing tear secretion, and restoring the ocular surface. Clinical and experimental studies have consistently demonstrated its efficacy and safety in improving tear production, relieving symptoms, repairing ocular surface structures, and slowing disease progression. This review summarizes the mechanisms, recent clinical evidence, and future perspectives of topical cyclosporine A in DED treatment, providing a reference for rational clinical use and novel therapeutic development.<\/jats:p>","DOI":"10.3389\/fopht.2025.1700163","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:20Z","timestamp":1763534300000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Cyclosporine a in the treatment of dry eye disease: a narrative review"],"prefix":"10.3389","volume":"5","author":[{"given":"Xiaoyan","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","volume-title":"Dry eye syndrome","author":"Golden","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"B4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/17512433.2025.2543380","article-title":"Current and emerging pharmacological treatment options for patients with dry eye disease","volume":"18","author":"Cukurova","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2025.07.004","article-title":"Prostaglandin F2alpha exacerbated dry eye by promoting lacrimal gland fibrosis progression through the activation of the RhoA\/ROCKs signaling pathway","volume":"38","author":"Guo","year":"2025","journal-title":"Ocul Surf"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.08.003","article-title":"TFOS DEWS II report executive summary","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200007270-00021","article-title":"Cyclosporine inhibits class II major histocompatibility antigen presentation by xenogeneic endothelial cells to human T lymphocytes by altering expression of the class II transcriptional activator gene","volume":"70","author":"Charreau","year":"2000","journal-title":"Transplantation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S173691","article-title":"Stability, safety, and transcorneal mechanistic studies of ophthalmic lyophilized cyclosporine-loaded polymeric micelles","volume":"13","author":"Shen","year":"2018","journal-title":"Int J Nanomedi"},{"key":"B9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11095-018-2556-5","article-title":"Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa(R)) for dry eye disease","volume":"36","author":"Mandal","year":"2019","journal-title":"Pharm Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3892\/etm.2021.10797","article-title":"Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities","volume":"22","author":"Jin","year":"2021","journal-title":"Exp Ther Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000133994.22392.47","article-title":"Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca","volume":"24","author":"Strong","year":"2005","journal-title":"Cornea"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0005","article-title":"Comparison of ocular surface mucin expression after topical ophthalmic drug administration in dry eye-induced mouse model","volume":"34","author":"Moon","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"CD010051","DOI":"10.1002\/14651858.CD010051.pub2","article-title":"Topical cyclosporine A therapy for dry eye syndrome","volume":"9","author":"de Paiva","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1998.0619","article-title":"Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice","volume":"68","author":"Yoshida","year":"1999","journal-title":"Exp Eye Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_3822_20","article-title":"Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation","volume":"69","author":"Mullick","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0002-9440(10)62232-8","article-title":"Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye","volume":"166","author":"Pflugfelder","year":"2005","journal-title":"Am J Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2006.02.004","article-title":"Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye","volume":"83","author":"De Paiva","year":"2006","journal-title":"Exp Eye Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4652(200009)184:3<400::AID-JCP15>3.0.CO;2-W","article-title":"Cyclosporine has a direct effect on the differentiation of a mucin-secreting cell line","volume":"184","author":"Phillips","year":"2000","journal-title":"J Cell Physiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.3","article-title":"Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine","volume":"31","author":"Iaccheri","year":"2017","journal-title":"Eye (Lond)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12898","article-title":"Increased corneal sub-basal nerve density in patients with Sjogren syndrome treated with topical cyclosporine A","volume":"45","author":"Levy","year":"2017","journal-title":"Clin Exp Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S279051","article-title":"A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1167\/tvst.7.5.24","article-title":"Once-daily cyclosporine-A-miDROPS for treatment of dry eye disease","volume":"7","author":"Coursey","year":"2018","journal-title":"Transl Vis Sci Technol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016710","article-title":"Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study","volume":"98","author":"Chen","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery","volume":"66","author":"Daull","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1039\/D1BM01453F","article-title":"A hybrid ocular delivery system of cyclosporine-A comprising nanomicelle-laden polymeric inserts with improved efficacy and tolerability","volume":"9","author":"Terreni","year":"2021","journal-title":"Biomater Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0234-x","article-title":"Micelles with ultralow critical micelle concentration as carriers for drug delivery","volume":"2","author":"Lu","year":"2018","journal-title":"Nat BioMed Eng"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/chem.201902619","article-title":"Ultra-high to ultra-low drug-loaded micelles: probing host-guest interactions by fluorescence spectroscopy","volume":"25","author":"Lubtow","year":"2019","journal-title":"Chemistry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"120007","DOI":"10.1016\/j.carbpol.2022.120007","article-title":"Oil-free eye drops containing Cyclosporine A\/cyclodextrin\/PVA supramolecular complex as a treatment modality for dry eye disease","volume":"297","author":"Chaudhari","year":"2022","journal-title":"Carbohydr Polym"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002633","article-title":"A water-free 0.1% Cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","volume":"141","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00228","article-title":"Hydrogel biomaterials for application in ocular drug delivery","volume":"8","author":"Lynch","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2219419","DOI":"10.1080\/10717544.2023.2219419","article-title":"Therapeutic applications of contact lens-based drug delivery systems in ophthalmic diseases","volume":"30","author":"Zhao","year":"2023","journal-title":"Drug Deliv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.2c00151","article-title":"Instant adhesion of amyloid-like nanofilms with wet surfaces","volume":"8","author":"Qin","year":"2022","journal-title":"ACS Cent Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11095-020-02872-2","article-title":"A novel eyes topical drug delivery system: csA-LNC for the treatment of DED","volume":"37","author":"Zhang","year":"2020","journal-title":"Pharm Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224805","article-title":"Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model","volume":"14","author":"Bang","year":"2019","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering11010039","article-title":"Current advances in regenerative strategies for dry eye diseases: A comprehensive review","volume":"11","author":"Bhujel","year":"2023","journal-title":"Bioeng (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2021.1966477","article-title":"The effect of OTX-101 on tear production in patients with severe tear-deficient dry eye disease: A pooled analysis of phase 2b\/3 and phase 3 studies","volume":"47","author":"Toyos","year":"2022","journal-title":"Curr Eye Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0146","article-title":"Efficacy of switching from cyclosporine A 0.05% Anionic emulsion to cyclosporine A 0.1% Cationic emulsion in patients with dry eye associated with sjogren's syndrome","volume":"37","author":"Kim","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(00)00035-x","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial","volume":"107","author":"Stevenson","year":"2000","journal-title":"Cyclosporin A Phase 2 Study Group Ophthalmol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737167.2025.2537850","article-title":"TearCare system versus cyclosporine ophthalmic emulsion for the treatment of moderate-to-severe meibomian gland disease associated dry eye disease in the United States: a cost-utility analysis","author":"Lighthizer","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_1850_24","article-title":"Comparative evaluation of aqueous solution and oil emulsion formulations of 0.05% cyclosporine eye drops in dry eye disease - A randomized clinical trial","volume":"73","author":"Salam","year":"2025","journal-title":"Indian J Ophthalmol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12886-025-03862-x","article-title":"Clinical efficacy of 0.1% cyclosporine A in dry eye patients with inadequate responses to 0.05% cyclosporine A: a switching, prospective, open-label, multicenter study","volume":"25","author":"Yoon","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1167\/iovs.64.12.30","article-title":"Bacillus-derived manganese superoxide dismutase relieves ocular-surface inflammation and damage by reducing oxidative stress and apoptosis in dry eye","volume":"64","author":"Yoon","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0145","article-title":"A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Chen","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"593","DOI":"10.18240\/ijo.2018.04.09","article-title":"Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction","volume":"11","author":"Kim","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-022-00906-3","article-title":"Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction","volume":"66","author":"Rhim","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.mjafi.2024.08.003","article-title":"Current paradigms in refractive surgery","volume":"80","author":"Namdev","year":"2024","journal-title":"Med J Armed Forces India"},{"key":"B48","doi-asserted-by":"publisher","first-page":"8150757","DOI":"10.1155\/2016\/8150757","article-title":"Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery","volume":"2016","author":"Lee","year":"2016","journal-title":"J Ophthalmol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000208818.47861.1d","article-title":"Ophthalmic cyclosporine use in ocular GVHD","volume":"25","author":"Lelli","year":"2006","journal-title":"Cornea"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0006","article-title":"Topical cyclosporine pretreatment of ocular surface in allogeneic hematopoietic stem cell transplant recipients","volume":"34","author":"Chun","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"165475","DOI":"10.1155\/2015\/165475","article-title":"Effects of long-term antiglaucoma eye drops on conjunctival structures: an in vivo confocal microscopy study","volume":"2015","author":"Zhu","year":"2015","journal-title":"J Ophthalmol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2018.1458923","article-title":"Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies","volume":"25","author":"Yu","year":"2018","journal-title":"Drug Deliv"},{"key":"B53","doi-asserted-by":"publisher","first-page":"114582","DOI":"10.1016\/j.addr.2022.114582","article-title":"Novel drug delivery systems for the management of dry eye","volume":"191","author":"Nagai","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000335281","article-title":"Cyclosporine a eye drop-induced elongated eyelashes: a case report","volume":"2","author":"Lei","year":"2011","journal-title":"Case Rep Ophthalmol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S113437","article-title":"Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature","volume":"11","author":"Rhee","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sjogren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001064","article-title":"Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjogren's syndrome","volume":"5","author":"Brito-Zeron","year":"2019","journal-title":"RMD Open"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31825e83f4","article-title":"Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits","volume":"32","author":"Daull","year":"2013","journal-title":"Cornea"},{"key":"B59","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/jop.2018.0106","article-title":"Ocular distribution of cyclosporine following topical administration of OTX-101 in New Zealand white rabbits","volume":"35","author":"Weiss","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"6640103","DOI":"10.1155\/2023\/6640103","article-title":"Nanoemulsion: an emerging novel technology for improving the bioavailability of drugs","volume":"2023","author":"Preeti","year":"2023","journal-title":"Scientifica (Cairo)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128357859250121120216","article-title":"Recent advances in cationic nanoemulsions for drug delivery: preparation, properties, and applications","volume":"31","author":"He","year":"2025","journal-title":"Curr Pharm Des"},{"key":"B62","doi-asserted-by":"publisher","first-page":"30224","DOI":"10.34172\/bi.2024.30224","article-title":"Oil-in-water nanoemulsions for glaucoma treatment: An insight into the latest trends","volume":"15","author":"Kishore","year":"2025","journal-title":"Bioimpacts"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.232","article-title":"Long-term outcome following cyclosporine-related neurotoxicity in paediatric allogeneic haematopoietic stem cell transplantation","volume":"52","author":"Straathof","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_15_18","article-title":"Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study","volume":"9","author":"Singla","year":"2019","journal-title":"Taiwan J Ophthalmol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S126668","article-title":"Dry eye syndrome: developments and lifitegrast in perspective","volume":"12","author":"Lollett","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"CD015070","DOI":"10.1002\/14651858.CD015070.pub2","article-title":"Topical corticosteroids for dry eye","volume":"10","author":"Liu","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4155\/tde.14.73","article-title":"Contact lenses as drug reservoirs & delivery systems: the successes & challenges","volume":"5","author":"ElShaer","year":"2014","journal-title":"Ther Deliv"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S300047","article-title":"Short-term therapeutic effects of topical corticosteroids on refractory dry eye disease: clinical usefulness of matrix metalloproteinase 9 testing as a response prediction marker","volume":"15","author":"Ryu","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"CD009729","DOI":"10.1002\/14651858.CD009729.pub2","article-title":"Over the counter (OTC) artificial tear drops for dry eye syndrome","volume":"2","author":"Pucker","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B70","doi-asserted-by":"publisher","first-page":"101375","DOI":"10.1016\/j.mtbio.2024.101375","article-title":"Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications","volume":"30","author":"Li","year":"2025","journal-title":"Mater Today Bio"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1700163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:21Z","timestamp":1763534301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1700163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":70,"alternative-id":["10.3389\/fopht.2025.1700163"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2025.1700163","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1700163"}}